|
|
16 June, 2005: Surface Logix has commenced a company-sponsored Phase I clinical trial for SLx-2101, an oral PDE-5 inhibitor, which is tested for treatment of cardiovascular diseases and endothelial dysfunction and erectile dysfunction.
The Phase I study is a single centre, randomized, double-blind study designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of orally administered SLx-2101 in healthy male subjects.
“The study would assess safety and tolerability of SLx-2101 and provide significant information on the potency and duration of action of SLx-2101 across a range of doses. We also hope to establish a preliminary indication of efficacy in established models of endothelial function," said Dr William Prince, chief development officer of the company.
“Although the Phase I study has just started, the first PK results look quite promising. Even at a dose of 5mg, we can detect a substantial amount of drug in the blood past 36 hours,” he said.
Dr Paul Sweetnam, CSO adds, “SLx-2101 is a highly-potent and selective compound with rapid cellular and tissue response and an extended duration of action.”
SLx-2101 is an oral phosphodiesterase-5 (PDE-5) inhibitor designed using Surface Logix’ proprietary small molecule Pharmacomer Technology.
|
